PDL sells assets, cuts jobs

Refocus, restructure--cut revenue? In the wake of its CEO's exit announcement, PDL BioPharma is selling all three of its marketed drugs and laying off 250 workers. By paring off Cardene (hypertension), Retavase (heart attacks), and Busulfex (leukemia), the company can focus on what it does best: develop antibody drugs for cancer and immune disorders. PDL acquired the three marketed products in its $325 million buyout of ESP Pharma.

PDL lost $160 million last year, and its chairman says near-term earnings will fall further with the sale of these drugs--but he doesn't expect much impact on the stock, because major shareholders had been asking the company to overhaul its strategy. So far, PDL shares have dropped 16 percent on the news.

- see PDL's release on the changes

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.